VNDA EBITDA Growth
Vanda Pharmaceuticals Inc · EBITDA Growth
VNDA EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-129.73%period ending
VNDA TTM EBITDA YoY % (-172.95% → -129.73%)
Year-over-year change
High-resolution chart · PNG
VNDA ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -129.7261% | |
| -220.8639% | |
| -721.2658% | |
| -771.4896% | |
| -1,090.2172% | |
| -6,072.0113% | |
| -258.188% | |
| -153.4976% | |
| -123.3696% | |
| -97.3757% | |
| -33.3785% | |
| 53.9662% | |
| 40.5304% | |
| -0.3934% | |
| -68.8971% | |
| -72.4425% | |
| -58.7038% | |
| -33.7167% | |
| 47.5602% | |
| 98.3485% | |
| 56.2564% | |
| 33.0653% | |
| 5.9166% | |
| -29.2229% | |
| 2.4774% | |
| 52.8499% | |
| 16.9029% | |
| 151.9347% | |
| 1,116.4258% | |
| 664.5215% | |
| 277.4122% | |
| 224.1025% | |
| 155.012% | |
| 22.169% | |
| -107.6533% | |
| 46.5559% | |
| 85.7745% | |
| 84.6601% | |
| 74.8301% | |
| 8.4766% | |
| -77.5053% | |
| 14.2067% | |
| 51.3776% | |
| 59.6029% | |
| 72.0788% | |
| 14.7895% | |
| -186.0254% | |
| -205.2969% | |
| -229.1138% | |
| -81.4347% | |
| 26.6237% | |
| 29.7329% | |
| 23.4146% | |
| -34.2354% | |
| -184.0026% | |
| -881.7009% | |
| -2,647.9827% | |
| -565.6658% | |
| -189.969% | |
| -2,397.0284% | |
| 111.6281% | |
| 116.7441% | |
| 129.5123% | |
| 100.359% | |
| 77.6695% | |
| 41.7668% | |
| 31.5155% | |
| 52.7823% | |
| 55.3371% | |
| 55.2409% | |
| 36.4094% | |
| 4.4142% | |
| -33.7713% | |
| -30.2477% | |
| -22.0068% | |
| -16.6359% | |
| -11.824% | |
| -74.8251% | |
| -172.9479% |